Year All202620252024202320222021202020192018 Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 15, 2026 Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference May 12, 2026 Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference May 11, 2026 Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones May 5, 2026 Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 1, 2026 Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain April 30, 2026 Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 13, 2026 Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones March 5, 2026 Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference March 3, 2026 Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 18, 2026
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference May 12, 2026
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference May 11, 2026
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones May 5, 2026
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain April 30, 2026
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones March 5, 2026
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference March 3, 2026
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 18, 2026
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)